Coverage policy updates

Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.

Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.

Recorded changes

86,510 on record

Recorded policy changes, newest first
Recorded	Payer	Policy	Change
May 14, 2026	HealthPartners	Oncology** - denosumab and biosimilars – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231698	New policy
May 14, 2026	HealthPartners	Oncology – PD-1 and PDL-1sPayerPolicy · HEALTHPARTNERS-CC-ENTRY-279798	New policy
May 14, 2026	HealthPartners	Oncology testing: solid tumors molecular diagnostics – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290096	New policy
May 14, 2026	HealthPartners	Oncology testing: solid tumors molecular diagnosticsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232482	New policy
May 14, 2026	HealthPartners	Oncology testing: solid tumors molecular diagnostics – Minnesota Health Care Programs – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-234410	New policy
May 14, 2026	HealthPartners	Oncology testing: hereditary cancer - Minnesota Health Care Programs – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-234385	New policy
May 14, 2026	HealthPartners	Oncology testing: hereditary cancerPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232707	New policy
May 14, 2026	HealthPartners	Oncology testing: hematologic malignancy molecular diagnosticsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-282189	New policy
May 14, 2026	HealthPartners	Oncology testing: cancer screening and surveillance – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290047	New policy
May 14, 2026	HealthPartners	Oncology testing: cancer screening and surveillancePayerPolicy · HEALTHPARTNERS-CC-ENTRY-232429	New policy
May 14, 2026	HealthPartners	Oncology testing: algorithmic assays – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-290355	New policy
May 14, 2026	HealthPartners	Oncology testing: algorithmic assaysPayerPolicy · HEALTHPARTNERS-CC-ENTRY-232428	New policy
May 14, 2026	HealthPartners	Oncology testing: algorithmic assays – Minnesota Health Care Programs – retire 06/30/2026PayerPolicy · HEALTHPARTNERS-CC-ENTRY-261028	New policy
May 14, 2026	HealthPartners	Oncology drug coverage – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-202906	New policy
May 14, 2026	HealthPartners	Oncology drug coveragePayerPolicy · HEALTHPARTNERS-CC-ENTRY-190828	New policy
May 14, 2026	HealthPartners	Oncology - trastuzumab (Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera), and trastuzumab and hyaluronidase-oysk (Herceptin Hylecta)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-237405	New policy
May 14, 2026	HealthPartners	Oncology - trabectedin (Yondelis) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-234241	New policy
May 14, 2026	HealthPartners	Oncology - teclistamab-cqyv (Tecvayli)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287054	New policy
May 14, 2026	HealthPartners	Oncology - talimogene laherparepvec (Imlygic) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-234242	New policy
May 14, 2026	HealthPartners	Oncology – blastic plasmacytoid dendritic cell neoplasm (BPDCN) drug therapy – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227133	New policy
May 14, 2026	HealthPartners	Oncology - blastic plasmacytoid dendritic cell neoplasm (BPDCN) drug therapyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-210226	New policy
May 14, 2026	HealthPartners	Oncology - tafasitamab-cxix (Monjuvi) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233977	New policy
May 14, 2026	HealthPartners	Oncology - sacituzumab govitecan-hziy (Trodelvy) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231639	New policy
May 14, 2026	HealthPartners	Oncology - polatuzumab Vedotin-piiq (Polivy) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233978	New policy
May 14, 2026	HealthPartners	Oncology - pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233979	New policy
May 14, 2026	HealthPartners	Oncology - pembrolizumab (Keytruda), pembrolizumab and berahyaluronidase alfa (Keytruda Qlex) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-228286	New policy
May 14, 2026	HealthPartners	Oncology - nivolumab (Opdivo) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231697	New policy
May 14, 2026	HealthPartners	Oncology - necitumumab (Portrazza)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-183254	New policy
May 14, 2026	HealthPartners	Oncology - moxetumomab pasudotox-tdfk (Lumoxiti)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-207225	New policy
May 14, 2026	HealthPartners	Oncology - mosunetuzumab-axgb (Lunsumio)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287053	New policy
May 14, 2026	HealthPartners	Oncology - lutetium lu 177 vipivotide tetraxetan (Pluvicto)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287052	New policy
May 14, 2026	HealthPartners	Oncology - luspatercept-aamt (Reblozyl) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-227132	New policy
May 14, 2026	HealthPartners	Oncology - luspatercept-aamt (Reblozyl) and imetelstat (Rytelo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-226974	New policy
May 14, 2026	HealthPartners	Oncology - lurbinectedin injection (Zepzelca) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-233980	New policy
May 14, 2026	HealthPartners	Oncology - long-acting G-CSF – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-228289	New policy
May 14, 2026	HealthPartners	Oncology - long-acting G-CSFPayerPolicy · HEALTHPARTNERS-CC-ENTRY-203757	New policy
May 14, 2026	HealthPartners	Oncology - lifileucel (Amtagvi)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-273417	New policy
May 14, 2026	HealthPartners	Oncology - isatuximab-irfc (Sarclisa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231645	New policy
May 14, 2026	HealthPartners	Oncology - ipilimumab (Yervoy)PayerPolicy · HEALTHPARTNERS-CC-AENTRY-046023	New policy
May 14, 2026	HealthPartners	Oncology - inotuzumab ozogamicin (Besponsa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-202917	New policy
May 14, 2026	HealthPartners	Oncology - gene therapy for bladder cancer (Adstiladrin)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-266662	New policy
May 14, 2026	HealthPartners	Oncology - gemcitabine intravesical system (Inlexzo)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-287010	New policy
May 14, 2026	HealthPartners	Oncology - fam-trastuzumab deruxtecan-nxki (Enhertu) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-226852	New policy
May 14, 2026	HealthPartners	Oncology - enfortumab vedotin-ejfv (Padcev) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-226865	New policy
May 14, 2026	HealthPartners	Oncology - emapalumab-lzsg (Gamifant)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-210222	New policy
May 14, 2026	HealthPartners	Oncology - datopotamab deruxtecan-dlnk (Datroway)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-284657	New policy
May 14, 2026	HealthPartners	Oncology - daratumumab and daratumumab hyaluronidase-fihj (Darzalex and Darzalex Faspro) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-231699	New policy
May 14, 2026	HealthPartners	Oncology - daratumumab and daratumumab hyaluronidase-fihj (Darzalex and Darzalex Faspro)PayerPolicy · HEALTHPARTNERS-CC-ENTRY-267748	New policy
May 14, 2026	HealthPartners	Oncology - copanlisib (Aliqopa) – Minnesota Health Care ProgramsPayerPolicy · HEALTHPARTNERS-CC-ENTRY-221634	New policy
May 14, 2026	HealthPartners	Oncology - chimeric antigen receptor/genetically engineered T-cell receptor (CAR-T) therapyPayerPolicy · HEALTHPARTNERS-CC-ENTRY-198232	New policy